Methadone and Buprenorphine-Associated Drug-Drug Interactions-Methadone and Buprenorphine=Associated Drug-Drug Interactions Presentation

Video Transcription

Video Summary

In this video presentation, Dr. Andrew Saxon, an addiction psychiatrist, discusses drug-drug interactions associated with methadone and buprenorphine. He begins by acknowledging Eleanor McCance-Katz for her research and contributions to the topic. Dr. Saxon mentions receiving a consulting fee from Indivior, the company that produces some brand name formulations of buprenorphine, but states that this financial relationship has been mitigated.<br /><br />The target audience for the presentation is healthcare professionals involved in the prevention and treatment of opioid use disorder. Dr. Saxon outlines the objectives, including providing epidemiological data on drug-drug interactions, explaining the causes of these interactions, describing the physiological and pharmacokinetic basis for adverse drug interactions, and exploring risk mitigation strategies for healthcare clinicians.<br /><br />He presents data on the leading causes of death and highlights the significant number of unintentional injuries, including poisonings and overdose, particularly related to opioid use. Dr. Saxon demonstrates trends in overdose deaths over the years, emphasizing the rise of synthetic opioids such as fentanyl in recent years.<br /><br />The presentation focuses on methadone in particular, discussing its potential for overdose and interactions with other medications, including sedatives, antidepressants, antipsychotics, alcohol, and stimulants. He also highlights the risks associated with combining methadone with antiretroviral medications used to treat HIV.<br /><br />Dr. Saxon explains the pharmacokinetic and pharmacodynamic basis for drug-drug interactions, providing examples of how medications can affect methadone and buprenorphine metabolism and increase the risk of adverse effects. He also mentions the potential for QT prolongation and arrhythmias with certain medications.<br /><br />The video concludes by offering recommendations for healthcare professionals to mitigate the risks of drug-drug interactions, including using non-opioid alternatives for pain management, educating patients and families, and avoiding the sharing of medications. Dr. Saxon also highlights the PCSS mentoring program and discussion forum as additional resources for clinicians seeking support and information on opioid use disorder treatment.<br /><br />Overall, the video provides a comprehensive overview of drug-drug interactions associated with methadone and buprenorphine, emphasizing the importance of awareness, education, and risk mitigation in providing safe and effective treatment for opioid use disorder.

Asset Subtitle

View the recorded presentation to attest that you have viewed the presentation in its entirety.

Keywords

Dr. Andrew Saxon

addiction psychiatrist

drug-drug interactions

methadone

buprenorphine

Eleanor McCance-Katz

healthcare professionals

opioid use disorder

epidemiological data